MedTrace Logo

Effects of Hemoadsorption on Vascular Integrity in Septic Shock

NCT07711197 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-07-17

No results posted yet for this study

Summary

This study aims to investigate the effects of adjunctive CytoSorb hemoadsorption therapy versus standard medical treatment on endothelial dysfunction in patients with refractory septic shock. The investigators hypothesize that hemoadsorption mitigates endothelial and glycocalyx injury by removing inflammatory mediators and other injurious circulating molecules, promoting hemodynamic stabilization.

Conditions

  • Septic Shock

Interventions

OTHER

Standard Medical Therapy (SMT)

Standard Medical Therapy according to local protocols based on the current international 'Surviving Sepsis Campaign' guidelines.

DEVICE

CytoSorb hemoadsorption

Target blood flow rate of 1.5 ml/kg/min, implemented either as a standalone extracorporeal treatment or integrated into a CRRT circuit (CVVHDF mode, preferably with regional citrate anticoagulation).

Sponsors & Collaborators

  • Ludwig Boltzmann Institute for Traumatology - The research center in cooperation with AUVA

    collaborator OTHER_GOV

  • Semmelweis University

    lead OTHER

Principal Investigators

  • Zsolt Molnár, Prof. Dr. · Department of Anaesthesiology and Intensive Therapy, Semmelweis University, Budapest, Hungary

  • Péter Hegyi, Prof. Dr. · Centre for Translational Medicine, Semmelweis University, Budapest, Hungary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-01
Primary Completion
2028-09-01
Completion
2029-01-01

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07711197 on ClinicalTrials.gov